CA
NZ
UK
AU
IND
US
Verastem Oncology, Inc. (NASDAQ:VSTM) traded up approximately 7.95 percent in pre-market activity, near $6.38 versus Wednesday's close of $5.91. Second quarter net product revenue reached $40.1 million, up sharply from $2.1 million a year earlier, driven by early sales of AVMAPKI FAKZYNJA CO PACK, …
Ardelyx, Inc. (NASDAQ:ARDX) traded down approximately 17.04 percent in pre-market activity, near $4.04 versus Wednesday's close of $4.87, extending a decline that began immediately after the company's after-hours release. Revenue of $118 to $121 million fell short of the $121.6 million consensus, while the …
Halozyme Therapeutics, Inc. (NASDAQ:HALO) traded around $90.00 in pre-market activity, up approximately 4.94 percent from Wednesday's close of $85.76. Total revenue grew 48 percent year over year to $481 million, well ahead of the roughly $404 million consensus, while non-GAAP EPS of $2.28 beat …
Organogenesis Holdings Inc. (NASDAQ:ORGO) traded down approximately 20.12 percent in pre-market activity, near $1.93 versus Wednesday's close of $2.41. Second quarter net product revenue fell 58 percent year over year to $42.8 million, with advanced wound care sales declining 61 percent, even as total …
QuidelOrtho Corporation (NASDAQ:QDEL) traded down approximately 20.34 percent in pre-market activity, near $13.00 versus Wednesday's close of $16.32. Second quarter revenue grew 2 percent to $630.9 million, or nearly 6 percent excluding China, and adjusted EPS of $0.13 beat the $0.04 loss estimate, but …
ResMed Inc. (NYSE:RMD) traded down approximately 7.81 percent before Thursday's open, near $205.80 versus Wednesday's close of $223.24, despite fourth quarter revenue growth of 9 percent to $1.5 billion and non-GAAP EPS of $2.95 topping the $2.90 estimate.
Starling Oncology, Inc. (NASDAQ:STLN), formerly The Oncology Institute, traded up approximately 37.06 percent in pre-market activity to $6.84 versus Wednesday's close of $4.99. The move follows both the company's rebrand, completed earlier this week, and a quarter that beat expectations on multiple fronts.
Trevi Therapeutics, Inc. (NASDAQ:TRVI) traded up approximately 7.03 percent in pre-market activity, near $19.80 versus Wednesday's close of $18.50. The move follows a second quarter net loss of $0.11 per share matching consensus, with no revenue reported given the company's pre-commercial stage.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) traded down approximately 7.61 percent in pre-market activity, near $76.34 versus Wednesday's close of $82.63. The decline is notable given the underlying quarter was strong, with revenue of $266.0 million topping the $260.1 million consensus and adjusted EPS of $2.21 …
Ginkgo Bioworks (NYSE:DNA) shares closed down 9.29% on August 6 at $8.50, with no new macro, sector, or company-specific catalyst identified for the day's decline. Ginkgo Bioworks is a Boston based biotechnology company that has built a leading horizontal platform for cell engineering and …
Please wait processing your request...